Lynparza (olaparib), already licensed for breast and ovarian cancer,it’s set to become the world’s first precision medicine for prostate cancer.
9 Gennaio 2020
A new clinical trial founds Lynparza (olaparib), the MSD and AstraZeneca PARP inhibitor, to slow or stop tumor development in men affected with advanced prostate
